News Quantified

MBIO – mustang bio, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Mustang Bio Receives Positive Listing Determination from Nasdaq

Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma

Mustang Bio Secures $4M through Strategic Warrant Agreement [Yahoo! Finance]

Mustang Bio Announces Exercise of Warrants for $4 Million Gross Proceeds

Form DEF 14A MUSTANG BIO, INC. For: Dec 26

Form 424B3 MUSTANG BIO, INC.

Form EFFECT MUSTANG BIO, INC.

Form S-3 MUSTANG BIO, INC.

Form 8-K MUSTANG BIO, INC. For: Nov 12

Top News Gainers

8/13 Mustang Bio Inc (NASDAQ: MBIO) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $7.00 price target on the stock. 36.5%

3/16 Form 10-K MUSTANG BIO, INC. For: Dec 31 30.7%

11/14 Mustang Bio Inc (NASDAQ: MBIO) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. 11.4%

6/20 Mustang Bio Inc (NASDAQ: MBIO) is now covered by analysts at Cantor Fitzgerald. They set a "buy" rating and a $7.00 price target on the stock. 9.8%

8/17 Mustang Bio files for $75M mixed shelf [Seeking Alpha] 8.4%

5/10 Q1/2019 3/31/2019 EPS -0.340 ZacksConsensus -0.370 ActVsEst 0.030 - Beat 8.3%

8/29 Mustang Bio to Present at September 2019 Investor Conferences 7.3%

8/16 Mustang Bio Inc (NASDAQ: MBIO) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. 6.0%

9/10 Form DEF 14C MUSTANG BIO, INC. For: Sep 10 5.3%

10/15 Mustang Bio Inc (NASDAQ: MBIO) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $3.25 price target on the stock. 3.6%

Top News Decliners

12/9 Mustang Bio Announces Updated Clinical Data on MB-107 Lentiviral Gene Therapy for Patients with X-Linked Severe Combined Immunodeficiency -17.7%

3/21 Mustang Bio Inc (NASDAQ: MBIO) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -11.4%

9/26 Mustang Bio to Participate in October 2019 Investor Conferences -11.2%

5/16 Mustang Bio and Nationwide Children’s Hospital Receive Orphan Drug Designation for MB-108 (Oncolytic Virus C134) for the Treatment of Malignant Glioma -10.0%

8/5 FDA Clears IND for Mustang Bio’s MB-102 (CD123 CAR T) -8.6%

8/12 Mustang Bio to Present at 11th Annual Bioprocessing Summit -8.5%

6/19 Form 8-K MUSTANG BIO, INC. For: Jun 18 -6.9%

8/22 Mustang Bio and St. Jude Children’s Research Hospital announce MB-107 lentiviral gene therapy for X-linked Severe Combined Immunodeficiency (XSCID) granted regenerative medicine advanced therapy (RMAT) designation from FDA -6.7%

2/27 Mustang Bio Inc (NASDAQ: MBIO) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -6.1%

5/17 Form SC 13D/A MUSTANG BIO, INC. Filed by: Fortress Biotech, Inc. -5.4%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day